Immunotherapy has gained attention due to the potential of immune checkpoint inhibitors in cancer treatment, and programmed death-1/programmed death ligand-1 (PD-1/PD-L1) is the important immune checkpoint for cancer treatment, which has been evidenced in a variety of malignant tumors, such as non-small cell lung cancer and melanoma. This evidence concerns the gene CD274 and cancer.